11.09.24 -- Life Science Leader Best Of October

An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment and return. However, it won't work for every company, as Abbas Kazimi, chief business officer at Nimbus Therapeutics, explains.

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape. 

Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, glaucoma, and Fragile X syndrome.

Antibody-based therapeutics are increasing in popularity. Analyze the hurdles of antibody development and manufacturing, and explore exciting developments.

Learn about three biosafety testing methods that are commonly applied: in vitro adventitious virus (IVV), species-specific virus testing such as minute virus of mice (MVM), and mycoplasma.

What steps is the biopharma industry taking to enhance sustainability? What challenges does biopharma encounter? And how can the entire industry draw lessons from the companies setting the standard?